Clinical trials: sponsored by Ipsen
Acromegaly
Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg
The study aims to evaluate the biochemical and clinical effectiveness on symptoms and tumor size of a monotherapy with Lanreotide 120mg in acromegalic subjects, to describe criteria for starting alternative strategies, and to…
- Trial name
- ACRO-OPTIM (NCT02698384)
- Where
- 10 sites in France
- Volunteers
- 4 people
- Sponsor
- Ipsen
Neuroendocrine Tumours
A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours
The objective of the PRELUDE study is to describe the use of lanreotide Autogel® (LAN ATG) combined with Peptide Receptor Radionuclide Therapy (PRRT) in the treatment of progressive neuroendocrine tumours located in the lung or…
- Trial name
- PRELUDE (NCT02788578)
- Where
- 12 sites in Australia, France and 3 more
- Volunteers
- 40 people
- Sponsor
- Ipsen
Prostate Cancer
Quality of Life of Patients With Locally Advanced and Metastatic Prostate Cancer
The purpose of this study is to evaluate possible changes in quality of life related to health (HRQL) in locally advanced and metastatic prostate cancer patients, after one year of follow-up.
- Trial name
- PROS-PROSQoLI (NCT02853409)
- Where
- 14 sites in Spain
- Volunteers
- 628 people
- Sponsor
- Ipsen
Gastroenteropancreatic Neuroendocrine Tumor
Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
An observational time and motion study in a clinical oncology setting is utilized in order to measure and compare product attributes and overall product efficiency between lanreotide and octreotide LAR.
- Trial name
- NCT03017690
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Ipsen
Neuroendocrine Tumors
Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in Spain
The objective of this study is to describe the use of resources and the costs associated with controlled or uncontrolled CS in patients with NETs in Spain.
- Trial name
- RECOSY (NCT03220087)
- Testing
- Data collection
- Where
- 28 sites in Spain
- Volunteers
- 142 people
- Sponsor
- Ipsen
Deep Infiltrating Endometriosis (DIE)
A Study to Describe the Efficacy of Diphereline Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months
The purpose of this study is to describe changes in the intensity of specific endometriosis symptoms from baseline pre-surgery to after surgery and subsequent continuous Diphereline (Triptorelin Acetate) treatment for up to 24…
- Trial name
- DIE-NIS (NCT01942369)
- Testing
- Triptorelin Acetate 3.75mg intramuscular injection
- Where
- 18 sites in China
- Volunteers
- 402 people
- Sponsor
- Ipsen
Acromegaly
Validation Study of the SAGIT® Instrument in Acromegaly
Patients will be treated in accordance with the standard medical practice of the hospital where they have been recruited during their participation in this study. No additional assessments or tests will be required.
- Trial name
- SAGIT (NCT02539927)
- Where
- 33 sites in United States, Belgium and 8 more
- Volunteers
- 227 people
- Sponsor
- Ipsen
Internal Endometriosis
Study of Diphereline 3.75 mg Treatment In Women Suffering From Internal Genital Endometriosis
To describe Gonadotropin-Releasing Hormone agonists (GnRH-a) treatment effectiveness on reduction of internal genital endometriosis symptom - menorrhagia - in different disease stages I, II, III in the Russian patient population…
- Trial name
- NCT03586063
- Testing
- Data collection
- Where
- 34 sites in Russia
- Volunteers
- 465 people
- Sponsor
- Ipsen
Spasticity
Study on the Use of Botulinum Toxin Type A in the Treatment of Chronic Post-stroke Spastic Patients
The purpose of this study is to document the effectiveness of treating chronic post-stroke spastic patients with Botulinum Toxin type A.
- Trial name
- B-CAUSE (NCT02390206)
- Where
- 11 sites in Brazil
- Volunteers
- 239 people
- Sponsor
- Ipsen